Production and characterization of newly developed alcohol-free topical liposome-gel transdermal drug delivery systems containing estradiol (E2)/ estriol (E3) for post-menopausal women

İsmail Aslan

Makale detayları

Production and characterization of newly developed alcohol-free topical liposome-gel transdermal drug delivery systems containing estradiol (E2)/ estriol (E3) for post-menopausal women

Yazarlar:

İsmail Aslan

Yayıncı:

Marmara University

Ana Başlıklar:

Pharmaceutical Delivery Technologies

Dergi:

Journal of Research in Pharmacy Vol.27 Issue 5, pp.2190-2198

Belge Tipi:

Makale

Yayın Tarihi:

6/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001346808

pISSN:

2630-6344

Anahtar kelimeler:

Özet:

 The aim of the research was to develop alcohol-free and relatively safe liposome-gel formulations containing Estradiol E2Estriol E3 combinations for menopausal women. Herewith, we purposed to solve problems some of the transdermal products containing ethanol by preparing liposome-gel formulations. The purpose of this research was the develop of liposome-gel formulations including Estradiol E2 Estriol E3 hormones. Mean particle size, zeta potential, FT-IR spectrum, rheological behaviour studies were evaluated in transdermal non-invasive formulation. The optimum formulation LH5 was concluded to be the negatively charged liposomes, which exhibited high physical characteristics, and relatively optimum particle size for transdermal penetration as 153.3 nm  1.1. Mean particle size distribution of empty liposome dispersion was smaller than E2E3 loaded liposomes LH6 because of encapsulation of them. So, the best E2E3 loaded formulation LH6 was selected according to the mean particle size distribution analysis, PDI values  0.5 PDI value PDI value was found as 0.371  0.01 for LH6. Moreover, since the zeta potential was found to be -54.9 mV 0.25, it is predicted to be more stable than other E2E3 loaded liposomes according to DLVO theory. When U21 and U30 used as gelling agent were compared, it was observed that U21 showed a more stable rheological behavior with approximately 25500 cP at skin pH. For this reason, U21 was preferred as a gelling agent for liposome dispersions in the second step. Considering the liposome-gel formulations, the LHG6 formulation, which is not excessively viscous in skin application compared to the other three formulations in terms of ease of transdermal application, was found to have a value of 34500 cP and was selected as the optimum liposome-gel formulation. Formulation and characterization studies supported that liposome gel delivery system is suitable for topical applications. All results supported that liposome-gel delivery system is more appropriate for transdermal applications. Since the liposome-gel transdermal drug delivery system is suitable and safer than oral administration in all characterization studies, efficacy studies of E2E3 loaded liposome-gel formulations will soon be possible with in- vivo studies in human volunteers.

 The aim of the research was to develop alcohol-free and relatively safe liposome-gel formulations containing Estradiol E2Estriol E3 combinations for menopausal women. Herewith, we purposed to solve problems some of the transdermal products containing ethanol by preparing liposome-gel formulations. The purpose of this research was the develop of liposome-gel formulations including Estradiol E2 Estriol E3 hormones. Mean particle size, zeta potential, FT-IR spectrum, rheological behaviour studies were evaluated in transdermal non-invasive formulation. The optimum formulation LH5 was concluded to be the negatively charged liposomes, which exhibited high physical characteristics, and relatively optimum particle size for transdermal penetration as 153.3 nm  1.1. Mean particle size distribution of empty liposome dispersion was smaller than E2E3 loaded liposomes LH6 because of encapsulation of them. So, the best E2E3 loaded formulation LH6 was selected according to the mean particle size distribution analysis, PDI values  0.5 PDI value PDI value was found as 0.371  0.01 for LH6. Moreover, since the zeta potential was found to be -54.9 mV 0.25, it is predicted to be more stable than other E2E3 loaded liposomes according to DLVO theory. When U21 and U30 used as gelling agent were compared, it was observed that U21 showed a more stable rheological behavior with approximately 25500 cP at skin pH. For this reason, U21 was preferred as a gelling agent for liposome dispersions in the second step. Considering the liposome-gel formulations, the LHG6 formulation, which is not excessively viscous in skin application compared to the other three formulations in terms of ease of transdermal application, was found to have a value of 34500 cP and was selected as the optimum liposome-gel formulation. Formulation and characterization studies supported that liposome gel delivery system is suitable for topical applications. All results supported that liposome-gel delivery system is more appropriate for transdermal applications. Since the liposome-gel transdermal drug delivery system is suitable and safer than oral administration in all characterization studies, efficacy studies of E2E3 loaded liposome-gel formulations will soon be possible with in- vivo studies in human volunteers.

 The aim of the research was to develop alcohol-free and relatively safe liposome-gel formulations containing Estradiol E2Estriol E3 combinations for menopausal women. Herewith, we purposed to solve problems some of the transdermal products containing ethanol by preparing liposome-gel formulations. The purpose of this research was the develop of liposome-gel formulations including Estradiol E2 Estriol E3 hormones. Mean particle size, zeta potential, FT-IR spectrum, rheological behaviour studies were evaluated in transdermal non-invasive formulation. The optimum formulation LH5 was concluded to be the negatively charged liposomes, which exhibited high physical characteristics, and relatively optimum particle size for transdermal penetration as 153.3 nm  1.1. Mean particle size distribution of empty liposome dispersion was smaller than E2E3 loaded liposomes LH6 because of encapsulation of them. So, the best E2E3 loaded formulation LH6 was selected according to the mean particle size distribution analysis, PDI values  0.5 PDI value PDI value was found as 0.371  0.01 for LH6. Moreover, since the zeta potential was found to be -54.9 mV 0.25, it is predicted to be more stable than other E2E3 loaded liposomes according to DLVO theory. When U21 and U30 used as gelling agent were compared, it was observed that U21 showed a more stable rheological behavior with approximately 25500 cP at skin pH. For this reason, U21 was preferred as a gelling agent for liposome dispersions in the second step. Considering the liposome-gel formulations, the LHG6 formulation, which is not excessively viscous in skin application compared to the other three formulations in terms of ease of transdermal application, was found to have a value of 34500 cP and was selected as the optimum liposome-gel formulation. Formulation and characterization studies supported that liposome gel delivery system is suitable for topical applications. All results supported that liposome-gel delivery system is more appropriate for transdermal applications. Since the liposome-gel transdermal drug delivery system is suitable and safer than oral administration in all characterization studies, efficacy studies of E2E3 loaded liposome-gel formulations will soon be possible with in- vivo studies in human volunteers.

 The aim of the research was to develop alcohol-free and relatively safe liposome-gel formulations containing Estradiol E2Estriol E3 combinations for menopausal women. Herewith, we purposed to solve problems some of the transdermal products containing ethanol by preparing liposome-gel formulations. The purpose of this research was the develop of liposome-gel formulations including Estradiol E2 Estriol E3 hormones. Mean particle size, zeta potential, FT-IR spectrum, rheological behaviour studies were evaluated in transdermal non-invasive formulation. The optimum formulation LH5 was concluded to be the negatively charged liposomes, which exhibited high physical characteristics, and relatively optimum particle size for transdermal penetration as 153.3 nm  1.1. Mean particle size distribution of empty liposome dispersion was smaller than E2E3 loaded liposomes LH6 because of encapsulation of them. So, the best E2E3 loaded formulation LH6 was selected according to the mean particle size distribution analysis, PDI values  0.5 PDI value PDI value was found as 0.371  0.01 for LH6. Moreover, since the zeta potential was found to be -54.9 mV 0.25, it is predicted to be more stable than other E2E3 loaded liposomes according to DLVO theory. When U21 and U30 used as gelling agent were compared, it was observed that U21 showed a more stable rheological behavior with approximately 25500 cP at skin pH. For this reason, U21 was preferred as a gelling agent for liposome dispersions in the second step. Considering the liposome-gel formulations, the LHG6 formulation, which is not excessively viscous in skin application compared to the other three formulations in terms of ease of transdermal application, was found to have a value of 34500 cP and was selected as the optimum liposome-gel formulation. Formulation and characterization studies supported that liposome gel delivery system is suitable for topical applications. All results supported that liposome-gel delivery system is more appropriate for transdermal applications. Since the liposome-gel transdermal drug delivery system is suitable and safer than oral administration in all characterization studies, efficacy studies of E2E3 loaded liposome-gel formulations will soon be possible with in- vivo studies in human volunteers.

Makale detayları

Production and characterization of newly developed alcohol-free topical liposome-gel transdermal drug delivery systems containing estradiol (E2)/ estriol (E3) for post-menopausal women

Yazarlar:

İsmail Aslan

Yayıncı:

Marmara University

Ana Başlıklar:

Pharmaceutical Delivery Technologies

Dergi:

Journal of Research in Pharmacy Vol.27 Issue 5, pp.2190-2198

Belge Tipi:

Makale

Yayın Tarihi:

6/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001346808

pISSN:

2630-6344

Liposome

transdermal

estradiol

estriol

menopause

Sayı

Makale detayları

Production and characterization of newly developed alcohol-free topical liposome-gel transdermal drug delivery systems containing estradiol (E2)/ estriol (E3) for post-menopausal women

Yazarlar: İsmail Aslan

Yayıncı: Marmara University

Ana Başlıklar: Pharmaceutical Delivery Technologies

Dergi: Journal of Research in Pharmacy Vol.27 Issue 5, pp.2190-2198

Belge Tipi: Makale

Yayın Tarihi: 6/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001346808

pISSN: 2630-6344

Liposome

transdermal

estradiol

estriol

menopause

Sayı

Yazarlar:

İsmail Aslan

Yayıncı:

Marmara University

Ana Başlıklar:

Pharmaceutical Delivery Technologies

Dergi:

Journal of Research in Pharmacy Vol.27 Issue 5, pp.2190-2198

Belge Tipi:

Makale

Yayın Tarihi:

6/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001346808

pISSN:

2630-6344